VEGF-R antibodies

Vascular endothelial growth factor (VEGF) signals through its receptor VEGF-R and plays a critical role during normal embryonic angiogenesis as well as in the pathological angiogenesis that occurs in a number of diseases including age related eye disease, wet AMD (advanced neovascular age-related macular degeneration), and cancer. Soluble VEGF-R-Fc (Eylea), invented by scientists at Regeneron, has been shown to be highly effective as a blocker to inhibit VEGF binding and signaling via VEGF-R. Eylea has been approved to treat age related wet AMD and cancer.

GenHunter has 2 monoclonal antibodies against Eylea (VEGF-R-Fc): a neutralizing mAb (NAb) and a binding mAb with specificity to human VEGF-R (vascular endothelial growth factor receptor).